Study of Biomarkers for Early Diagnosis and Patient Stratification in Ankylosing Spondylitis, Rheumatoid Arthritis, and Systemic Lupus Erythematosus

What this Trial Is About

Researchers are studying three inflammatory rheumatic diseases Ankylosing Spondylitis AS, Rheumatoid Arthritis RA, and Systemic Lupus Erythematosus SLE. Early diagnosis of these diseases is difficult but crucial for better outcomes. The study aims to identify new biomarkers that can help diagnose these diseases sooner, improving patient care and treatment strategies by using a transcriptomic approach on blood samples. The study will analyze blood samples from patients with confirmed diagnoses of AS, RA, and SLE, along with healthy controls matched by age and gender. Researchers will use advanced methods to find specific biomarkers for each disease and develop a diagnostic chip to aid clinical practice. Results will be validated using quantitative real-time protein chain reaction and tested on new patient groups. Participants will provide biological samples and undergo assessments to help researchers identify transcriptomic signatures that distinguish the three diseases. The study will measure these signatures over 12 weeks while monitoring disease activity. The goal is to improve patient stratification and discover new therapeutic targets. The study includes healthy volunteers and lasts from enrollment until 12 weeks later.

Biomarkers in Inflammatory Rheumatic Diseases Diagnosis